Editorial Article
Three of the Largest Crop Protection Businesses Held Margin in the Worst Pricing Year in a Decade. The Fourth Did Not.
2025 was the worst pricing year in crop protection in a decade. Glyphosate technical traded near RMB 26,000 a tonne. Generic competition compressed every post-patent class. And three of the four largest businesses in the industry finished the year with margin intact or higher.
Bayer Crop Science held a 19.4 per cent core crop protection margin. BASF made 7.4 per cent more EBITDA on 2.2 per cent less revenue. Corteva’s crop protection EBITDA rose 6 per cent with margin up 70 basis points. The fourth, FMC, saw revenue fall 18 per cent and spent the year restructuring. The divergence inside one industry, in one year, is the most informative thing in the sector.
| Crop protection revenue | Profit measure | Price / volume | |
|---|---|---|---|
| Syngenta Group | USD 13.7bn, +4% | 1,800+ approvals secured | Latin America −1% / −3% on generic pricing |
| Bayer Crop Science | EUR 7,934m core CP, −4% | 19.4% core CP margin | Insecticides −12.2%, fungicides −4.8% |
| Corteva | USD 7,503m | EBITDA USD 1,350m, +6%, margin +70bp | Market price −2% in Latin America |
| BASF | EUR 9,587m, −2.2% | EBITDA EUR 2,081m, +7.4% | Volumes +3.0%, prices −1.2% |
| FMC | USD 3.47bn, −18% | Adjusted EBITDA USD 843m | −8% excluding India |
The margin is a cost position, not pricing power
BASF is the cleanest illustration. Volumes rose 3.0 per cent, prices fell 1.2 per cent, revenue fell 2.2 per cent after portfolio effects — and EBITDA rose 7.4 per cent. That is not a company holding price. That is a company running its plants harder while its input costs, freight and energy came off the peak, and letting the spread do the work.
The same arithmetic appears at Corteva, where crop protection EBITDA grew 6 per cent on flat-to-down revenue and margin expanded 70 basis points, and at Bayer, where a 19.4 per cent core crop protection margin survived a year in which insecticides fell 12.2 per cent on the Movento patent expiry and fungicides fell 4.8 per cent. Those are portfolio events, not demand events. The underlying molecule business was more resilient than the headline declines suggest.
Which is the point that matters for anyone reading margin as evidence of pricing power. It is not. In a deflating category, a fixed-cost base that is being sweated produces higher margins on lower revenue. That looks like strength for two or three years and then stops, because there is a floor to how much plant you can idle before the incremental tonne disappears.
What happened to the fourth one
FMC’s year is the counter-example that proves the rule, because FMC did not have the same levers. Revenue fell 18 per cent, 8 per cent excluding India. The company divested its India business, is rebuilding its Brazilian channel around a direct-to-grower model, and carried bad debt through SG&A — three structural problems that no amount of plant utilisation fixes. Its response, Project Foundation, is a cost programme, which is what a company runs when the portfolio does not have a spread to lean on.
The industry’s own explanation for the difference is portfolio mix. The honest version is scale and channel control. Companies selling technical material into distributors who can buy from forty other suppliers have no price; companies selling a formulated programme with a service wrapper have some.
The loss showed up in capital, not in the income statement
Here is the number that reframes the whole year. Bayer booked EUR 5,773 million of special items in the crop science division against EUR 4,188 million of underlying EBITDA. The impairment is roughly 1.4 times the division’s entire underlying profit.
That is not a trading loss. It is an admission about the price of the assets — the multiple paid for a business whose category turns out to deflate about 1.3 per cent a year in unit value. The operating business made money. The capital structure built on the assumption of pricing power did not.
Why this sets a 4.12 per cent forecast
The Global Crop Protection report sizes this market at USD 72.40 billion in 2025 rising to USD 100.00 billion by 2033 at 4.12 per cent, with volume growing 1.88 per cent. That rate is only defensible if you read margin the way the table above reads it: as a cost position that can be defended for a while, on a category where price falls structurally.
Three of these companies will keep earning a mid-teens to low-twenties margin because they can run assets hard and sell programmes. The category will keep losing unit value because capacity exists that nobody will retire. Both things are true at once, and any forecast that resolves the contradiction in one direction — either a pricing recovery or a collapse in profitability — is going to be wrong.
The full competitive chapter, company tables and eight-year value path are in the Global Crop Protection Market report.
Frequently Asked Questions
Why did margins hold while prices fell?
Because margin in this category measures cost position rather than pricing power. BASF grew volumes 3.0 per cent while prices fell 1.2 per cent and revenue fell 2.2 per cent, and still raised EBITDA 7.4 per cent — a fixed-cost base being sweated as raw material, freight and energy costs came off the peak. That works for two or three years and then hits the floor of how much plant can be idled.
Why did FMC fare worse than Bayer, BASF and Corteva?
FMC's revenue fell 18 per cent, 8 per cent excluding India. It divested its India business, is rebuilding its Brazilian channel on a direct-to-grower model and carried bad debt through SG&A. Those are structural problems that plant utilisation does not fix, and its response — Project Foundation — is a cost programme rather than a portfolio lever.
What does Bayer's EUR 5,773 million charge actually represent?
Bayer booked EUR 5,773 million of special items in the crop science division against EUR 4,188 million of underlying EBITDA — roughly 1.4 times the division's entire underlying profit. That is an impairment of the assets, not a trading loss. The operating business made money; the multiple paid for it assumed pricing power the market has since contradicted.
How does this support a 4.12 per cent market forecast?
Because it reconciles two facts that appear contradictory. Three of the four largest businesses can hold mid-teens to low-twenties margins by running assets hard and selling programmes, while the category keeps losing unit value at about 1.3 per cent a year because capacity exists that nobody will retire. A 4.12 per cent value CAGR with 1.88 per cent volume growth, and the remaining 54 per cent from mix, is what that combination produces.